0
Real-time compression monitoring devices today
13%
Patients still develop Radial Artery Occlusion
3+hrs
Manual, intermittent monitoring per patient
14.5M+
Transradial procedures performed worldwide each year
The Compression Process Today
The Last Step of Every Transradial Procedure Is Still Done Blind
Transradial cardiac catheterization is the global standard. More than 14.5 million procedures are performed each year, trending past 18 million as wrist access converts the last of the groin procedures and global TR penetration moves toward 95 percent. The clinical access route is solved.
The post-procedural compression process is not. Compression bands are applied without measurement. Hemostasis is judged by hours of intermittent nurse checks. Patent Hemostasis, now endorsed by every major cardiology society worldwide, is achieved inconsistently because the tool to achieve it reliably does not exist.
IdaFlo TR is that tool. A continuous, real-time radial flow monitor positioned distal to any existing compression band. Patent Hemostasis from minute one becomes the operating state. Shorter hemostasis time, lower nursing workload, faster same-day discharge, and a preserved radial artery for life are the consequences. Reduced Radial Artery Occlusion (RAO) is one of those consequences, not the entire reason to care.
Patent Hemostasis is two requirements held simultaneously: keep the artery open, and stop the bleeding. Compression bands solved the bleeding half nearly two decades ago. The other half, keeping the artery open during compression, has been delivered by inference ever since.
IdaFlo TR closes that gap
Strategic Activity
The medtech market is actively investing in post-procedural standardization. Public transactions in 2025 priced this category at multiple billions in opportunity, with explicit acquirer language about standardizing, simplifying, and minimizing post-procedure care.
Expansion
Interventional radiology, neurointervention, and peripheral vascular are adopting transradial access. Each new specialty inherits the same unmeasured compression problem without the lessons learned in cardiology over the last two decades.
Recognition
Every major cardiology society endorses Patent Hemostasis as the recommended standard of care. The 2026 DGK position paper (Breitbart et al., Kardiologie 2026;20:54-61) recommends Patent Hemostasis as the central prevention strategy and describes only manual, intermittent verification methods. Despite current practice, RAO incidence remains approximately 13 percent across 30,000+ patients in a meta-analysis of 41 studies (Khalid et al. 2024).
Sustainability
Transradial access has moved from optional technique to standing infrastructure. Global penetration has gone from 20 percent in 2013 to about 70 percent in 2026, weighted across cardiology markets, and is trending toward 95 percent and beyond. A radial-first generation of interventionalists is now in practice, and the generation behind them knows no other access route. Adoption is a demographic trend, not a wish.
Why Now.
Five Forces Converging on the Compression Process.
The integrated low-power wireless and sensing electronics required for a true single-use disposable wristband were too large and too expensive when the clinical mandate first formed. Generational miniaturization has closed the cost and size gap. A clinical-grade disposable sensor is buildable today in a way it was not even five years ago.
Technology Readiness
Preserve the Artery
Radial artery patency matters now, not only later. Even when collateral flow from the ulnar artery keeps the hand viable, occluded radial arteries can produce upper-limb symptoms ranging from mild discomfort to clinically significant complaints (Wiper et al., Catheter Cardiovasc Interv 2019). Beyond the immediate sequelae, half of these patients will need that artery back. Many within a year, when progressive coronary disease, repeat ischemia, or in-stent restenosis brings them back to the cath lab. The rest later, when the radial is the preferred second conduit for coronary bypass surgery, or the access path for arteriovenous fistulas in dialysis. Every preserved artery is a future surgical option protected, across cardiology, interventional radiology, neurointervention, and dialysis access.
Accelerate Throughput
Faster, more confident same-day discharge. Bed-hours reclaimed. Workflow aligned with the migration of cardiac procedures into ambulatory and outpatient settings. Nursing capacity freed for higher-acuity work.
Standardize the Process
Patent Hemostasis from minute one. Real-time data replaces operator inference. The same evidence-based protocol for every patient, every shift, every operator. Variability drops. Nursing touches drop. Hemostasis time drops.
The Triple Cath Lab ROI
What our Clients Say
“IdaFlo TR promises to set the Guided Compression standard for post transradial procedure compression protocols giving us the tool to achieve patent hemostasis for every patient”
— Giovanni Amoroso, MD, PhD Interventional Cardiologist, OLVG Hospital Amsterdam, The Netherlands
What our Clients Say
We are interested in evaluating this technology in hopes of integrating this potentially valuable monitoring tool into our standard protocols for managing radial artery catheterization procedures”
— Dr. Jim Nolan, Interventional Cardiologist,
Keele University, UK
What our Clients Say
IdaFlo TR is a significant advancement in radial artery management. Real-time blood flow monitoring has the potential to reduce RAO rates, streamline protocols, and improve outcomes. I’m excited for its clinical trials and the opportunity to transform transradial care.”
— Prof. Stephane Carlier, Interventional Cardiologist, University of Mons (UMONS) Mons, Belgium
Patient Outcomes
-
Patent Hemostasis from minute one
-
Lower Radial Artery Occlusion risk
-
Preserved upper-limb circulation in the weeks and months after the procedure (Wiper et al., Catheter Cardiovasc Interv 2019)
-
A radial artery available for the procedures the patient has not had yet
Cath Lab Performance
-
Shorter hemostasis time (Takamatsu et al. 2023: 190 min to 66 min)
-
Faster same-day discharge
-
Less nursing labor per patient
-
A standardized, auditable compression record for every procedure
Every benefit IdaFlo TR delivers comes from one mechanism: continuous, real-time radial artery flow monitoring during compression, positioned distal to any existing compression band. Two clinical benefits follow.
Two Clinical Benefits.
One Mechanism.
Distribution
Distribution partners engaged across the European Union, with a partner in place for the United States market. Pre-approval clinical pilots active at Centers of Excellence in four countries.
Manufacturing
Relitech BV, the Netherlands, is our primary manufacturing and MVP development partner. Non-sterile disposable manufactured in a clean-room environment.
Intellectual Property
Granted patent family with composition-of-matter and method protection extending into the late 2030s and beyond, across the United States, the European Union, Japan, China, and India.
Regulatory
FDA 510(k) pathway, Class II. CE mark under MDR planned for the European Union. PMA explicitly ruled out. Pre-submission underway with regulatory partner.
At a Glance
Need
more details?
We are here to assist. Contact us by phone, e-mail or via our social media channels.
IDAHealth Inc. is a U.S. Delaware C-Corporation with European operations in The Netherlands.
Registered address: 16192 Coastal Highway, Lewes, DE 19958, USA.
European office: Van Siburgstraat 34, 3863 HW Nijkerk, The Netherlands.
Call us:
+1 9548062962